News | January 18, 2013

Compact Proton Therapy Technology Achieves Milestone of Beam at Gantry Room Isocenter

ProTom Radiance 330

January 18, 2013 — Testing of a compact cancer treatment technology from ProTom International Inc. has demonstrated that the system achieves its design specification: delivering high-energy protons to isocenter at a beam intensity sufficient for standard clinical practice. The ProTom technical team measured stable and reproducible performance on the Radiance 330 proton therapy system at the McLaren Proton Therapy Center (MPTC) in Flint, Mich. This is the first time that ProTom has tested its compact system’s gantry beam optics design.

“Measuring high beam intensities at isocenter indicates well-functioning integration among various subsystems of the Radiance 330 necessary for clinical implementation,” said Vahagn Nazaryan, Ph.D., senior vice president of physics for ProTom. “We delivered beam through the gantry and nozzle in the first of three gantry treatment rooms as part of validation and verification of our technical design. We are pleased that the system performed as designed and quickly achieved a dose rate sufficient for standard clinical practice.”

“We are excited by the results of successful beam transport testing through our first gantry treatment room: these results were independently reproduced by our clinical physics team,” said Sung Park, Ph.D., chief physicist for McLaren Cancer Institute.

Earlier in the summer, ProTom installed a new custom-designed radiofrequency quadrupole (RFQ) proton linear accelerator (linac) injector from AccSys Technology Inc. This upgrade has significantly improved accelerated proton beam intensities. The RFQ upgrade resulted in an increase in injection intensity, yielding in excess of several times the number of protons per cycle accelerated in the synchrotron, with further tuning and optimization ongoing at McLaren.

“Both the ProTom and McLaren teams are to be commended for achieving this very significant result, which continues to validate that the system is performing as it was designed,” said ProTom CEO Stephen L. Spotts. “ProTom is focused on final validation and testing in order to secure all regulatory clearances necessary for clinical operation. It is my firm belief that our Radiance 330 system is not only the most advanced proton beam scanning system available but the most economical solution as well.“

The Radiance 330 proton therapy system has not been cleared by the U.S. Food and Drug Administration (FDA) for commercial distribution in the United States at this time.

For more information: www.protominternational.com, www.mclaren.org

Related Content

Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
News | Brachytherapy Systems | June 07, 2018
IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.
Raysearch RayStation
Feature | Radiation Therapy | June 05, 2018 | By Melinda Taschetta-Millane
Treatment planning systems are at the heart of r...
Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer
News | Proton Therapy | May 31, 2018
Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at...
More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage
News | Proton Therapy | May 25, 2018
The Alliance for Proton Therapy Access has released a national report revealing the heavy emotional and financial...
News | Treatment Planning | May 24, 2018
Daniela Schmitt, Ph.D., took top honors in the overall category of the 2018 TROG Plan Study: Stereotactic Radiosurgery...
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
Mercy Signs Multi-System, Multi-Hospital Agreement for Accuray Radiotherapy Systems
News | Radiation Therapy | May 16, 2018
Accuray Inc. signed a multi-system, multi-hospital agreement with Mercy for the acquisition of Accuray Radixact and...
Overlay Init